CureVac announced the second- and third-phase trial results for its CVnCoV vaccine on Wednesday, in its final analysis for a…
Preliminary results from second and third-phase trials on 40,000 subjects in 10 countries of Europe and Latin America show that…
The randomized and placebo-controlled trial called Herald may include more than 35,000 participants in Europe and Latin America, the Tübingen-based…